Abstract
Here, the anticoagulant activities of oroxylin A (OroA), a major component of Scutellaria baicalensis Georgi, were examined by monitoring activated partial thromboplastin time (aPTT), prothrombin time (PT), and the activities of cell-based thrombin and activated factor X (FXa). Furthermore, the effects of OroA on the expressions of plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-PA) were tested in tumor necrosis factor (TNF)-α activated human umbilical vein endothelial cells (HUVECs). Treatment with OroA resulted in prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and OroA inhibited production of thrombin and FXa in HUVECs. And OroA inhibited thrombin-catalyzed fibrin polymerization and platelet aggregation. In accordance with these anticoagulant activities, OroA elicited anticoagulant effects in mouse. In addition, treatment of OroA resulted in the inhibition of TNF-α-induced production of PAI-1, and treatment with OroA resulted in the significant reduction of the PAI-1 to t-PA ratio. Collectively, OroA possess antithrombotic activities and offer bases for development of a novel anticoagulant.
Similar content being viewed by others
References
Antovic, A. 2010. The overall hemostasis potential: A laboratory tool for the investigation of global hemostasis. Seminars in Thrombosis and Hemostasis 36: 772–779.
Bae, J.S. 2011. Antithrombotic and profibrinolytic activities of phloroglucinol. Food and Chemical Toxicology 49: 1572–1577.
Bae, J.S., and A.R. Rezaie. 2008. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thrombosis and Haemostasis 100: 101–109.
Davie, E.W. 1995. Biochemical and molecular aspects of the coagulation cascade. Thrombosis and Haemostasis 74: 1–6.
Davie, E.W., K. Fujikawa, and W. Kisiel. 1991. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 30: 10363–10370.
Dejana, E., A. Callioni, A. Quintana, and G. De Gaetano. 1979. Bleeding time in laboratory animals. II—A comparison of different assay conditions in rats. Thrombosis Research 15: 191–197.
Esmon, C.T. 2001. Role of coagulation inhibitors in inflammation. Thrombosis and Haemostasis 86: 51–56.
Esmon, C.T. 2005. The interactions between inflammation and coagulation. British Journal of Haematology 131: 417–430.
Ghosh, S., M. Ezban, E. Persson, U. Pendurthi, U. Hedner, and L.V. Rao. 2007. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. Journal of Thrombosis and Haemostasis 5: 336–346.
Hamaguchi, E., T. Takamura, A. Shimizu, and Y. Nagai. 2003. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. Journal of Pharmacology and Experimental Therapeutics 307: 987–994.
Kim, S.Y., S. Kim, J.M. Kim, E.H. Jho, S. Park, D. Oh, and H.S. Yun-Choi. 2011. PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Rep 44: 140–145.
Kim, T.H., S.K. Ku, and J.S. Bae. 2012. Antithrombotic and profibrinolytic activities of eckol and dieckol. Journal of Cellular Biochemistry 113: 2877–2883.
Lee, W., E.J. Yang, S.K. Ku, K.S. Song, and J.S. Bae. 2012. Anticoagulant activities of oleanolic acid via inhibition of tissue factor expressions. BMB Reports 45: 390–395.
Li, H.N., F.F. Nie, W. Liu, Q.S. Dai, N. Lu, Q. Qi, Z.Y. Li, Q.D. You, and Q.L. Guo. 2009. Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo. Toxicology 257: 80–85.
Li, C., G. Lin, and Z. Zuo. 2011. Pharmacological effects and pharmacokinetics properties of Radix Scutellariae and its bioactive flavones. Biopharmaceutics & Drug Disposition 32: 427–445.
Lopez, S., F. Peiretti, B. Bonardo, I. Juhan-Vague, and G. Nalbone. 2000. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152: 359–366.
Lu, Z., N. Lu, C. Li, F. Li, K. Zhao, B. Lin, and Q. Guo. 2012. Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicology Letters 209: 211–220.
Northup, P.G., V. Sundaram, M.B. Fallon, K.R. Reddy, R.A. Balogun, A.J. Sanyal, Q.M. Anstee, M.R. Hoffman, Y. Ikura, and S.H. Caldwell. 2008. Hypercoagulation and thrombophilia in liver disease. Journal of Thrombosis and Haemostasis 6: 2–9.
Novak, E.K., H.O. Sweet, M. Prochazka, M. Parentis, R. Soble, M. Reddington, A. Cairo, and R.T. Swank. 1988. Cocoa: A new mouse model for platelet storage pool deficiency. British Journal of Haematology 69: 371–378.
Nowak, P., H.M. Zbikowska, M. Ponczek, J. Kolodziejczyk, and B. Wachowicz. 2007. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: Functional consequences. Thrombosis Research 121: 163–174.
Philip-Joet, F., M.C. Alessi, C. Philip-Joet, M. Aillaud, J.R. Barriere, A. Arnaud, and I. Juhan-Vague. 1995. Fibrinolytic and inflammatory processes in pleural effusions. European Respiratory Journal 8: 1352–1356.
Quinn, C., J. Hill, and H. Hassouna. 2000. A guide for diagnosis of patients with arterial and venous thrombosis. Clinical Laboratory Science 13: 229–238.
Rao, L.V., S.I. Rapaport, and M. Lorenzi. 1988. Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71: 791–796.
Schleef, R.R., M.P. Bevilacqua, M. Sawdey, M. A. Gimbrone Jr., and D.J. Loskutoff. 1988. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Journal of Biological Chemistry 263: 5797–5803.
Schouten, M., W.J. Wiersinga, M. Levi, and T. Van Der Poll. 2008. Inflammation, endothelium, and coagulation in sepsis. Journal of Leukocyte Biology 83: 536–545.
Sugo, T., C. Nakamikawa, S. Tanabe, and M. Matsuda. 1995. Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: Its catalytic efficiency is similar to that of prothrombinase complex on platelets. Journal of Biochemistry 117: 244–250.
Sun, Y., N. Lu, Y. Ling, Y. Gao, Y. Chen, L. Wang, R. Hu, Q. Qi, W. Liu, Y. Yang, Q. You, and Q. Guo. 2009. Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. European Journal of Pharmacology 603: 22–28.
Tseng, T.L., M.F. Chen, M.J. Tsai, Y.H. Hsu, C.P. Chen, and T.J. Lee. 2012. Oroxylin-A rescues LPS-induced acute lung injury via regulation of NF-kappaB signaling pathway in rodents. PLoS ONE 7: e47403.
Acknowledgments
This study was supported by the National Research Foundation of Korea (NRF) funded by the Korean government [MEST] (Grant Nos. 2012-0009400) and by the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant No. A111305).
Conflict of interest
The authors have no conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ku, SK., Lee, IC. & Bae, JS. Antithrombotic activities of oroxylin A in vitro and in vivo. Arch. Pharm. Res. 37, 679–686 (2014). https://doi.org/10.1007/s12272-013-0233-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-013-0233-0